Media Center

May 2024 - #1 Amazon bestseller status has been awarded to an Elastrin co-founder's book Discovering the Nature of Longevity: Restoring the heart and body by targeting hidden stress . Douglas Mulhall's book is the first to reveal for a general audience the mysteries of elastin, along with the groundbreaking discoveries by Elastrin's CSO Dr. Naren Vyavahare. The book also chronicles co-invention by Dr. Charles Rice and Dr. Vyavahare of an antibody specific for damaged elastin

Elastrin Therapeutics Inc. closes $10M Funding Round

CLEMSON, S.C. & BERLIN--( BUSINESS WIRE )--Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again. It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level. Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the trea

Elastrin's Chief Scientific Officer Prof. Naren Vyavahare was granted USD 2.2 million from the National Institutes of Health to advance his research on reversing calcification by use of targeted nanoparticles. As Hunter Endowed Chair of Bioengineering at Clemson University and Director of the Bioengineering Center for Regeneration and Formation of Tissues (SC BioCRAFT) Prof. Vyavahare has a long standing relationship with the NIH that goes back more than two decades. Credit:

The South Carolina Research Authority (SCRA) has granted Elastrin $25.000 in financial support through its Academic Start-up Assistance Program (ASAP), showing confidence in our technology. SCRA is a public, non-profit corporation by the State of South Carolina that fosters South Carolina’s Innovation Economy by supporting entrepreneurs, enabling academic research and its commercialization, and connecting innovators to industry. On behalf of their entrepreneurial program SC L